Isolation, identification and characterisation of strains with probiotic activity, from faeces of infants fed exclusively with breast milk

Abstract

The invention relates to probiotic micro-organisms isolated from faeces of children exclusively fed with breast milk. Said microorganisms are used in the food or pharmaceutical industry, especially for use in infant formula milk, due to their probiotic properties which have beneficial effects on the health of those ingesting them. Said microorganisms consist of Lactobacillus rhamnosus HERO 22A (CNCM I-4036), Lactobacillus paracasei HERO 7 (CNCM I-4034) and Bifidobacterium breve HERO 15B (CNCM I-4035).

1 . A strain of probiotic microorganism isolated from faeces of children exclusively fed with breast milk characterized by consisting of  Bifidobacterium breve  HERO 15B (CNCM I-4035). 
     
     
         2 - 4 . (canceled) 
     
     
         5 . The strain of microorganism according to  claim 1  characterized by being presented in the form of pure biological culture. 
     
     
         6 . The strain of microorganism according to  claim 1  characterized by being isolated. 
     
     
         7 . The strain of probiotic microorganism according to  claim 1  characterized by being presented in the form of viable cells. 
     
     
         8 . The strain of probiotic microorganism according to  claim 1 , characterized by being presented in the form of non-viable cells. 
     
     
         9 - 16 . (canceled) 
     
     
         17 . The strain of probiotic microorganism according to  claim 1  for use in diets. 
     
     
         18 . The strain according to  claim 17  characterized in that the use thereof in infant and/or adult and/or special diets. 
     
     
         19 . The strain according to  claim 18  for use in the preparation of infant formula milk. 
     
     
         20 . The strain according to  claim 19 , characterized in that the formula milk consist of ready-to-eat infant milk and/or infant cereals, and/or infant foods. 
     
     
         21 . The strain according to  claim 17  for use in the preparation of food supplements. 
     
     
         22 . The strain according to  claim 17  for use in the preparation of special formulas for oral and/or enteral nutrition. 
     
     
         23 . The strain of probiotic microorganism according to  claim 1  for use in the preparation of a pharmaceutical product. 
     
     
         24 . The strain of probiotic microorganism according to  claim 1  applicable in stimulating the immune system and/or in preventing/treating asthma and/or in preventing/treating gastrointestinal disorders, and/or in eliminating/modulating the main digestive pathogens, and/or in preventing/treating obesity and its co-morbidities including metabolic syndrome and diabetes and/or in the typical aging-associated diseases. 
     
     
         25 . The strain according to  claim 24 , characterized in that said gastrointestinal disorders comprise alterations of intestinal transit such as constipation and alterations of the bioavailability of minerals, infections and malabsorption syndromes. 
     
     
         26 . The strain according to  claim 25 , characterized in that said infections comprise gastric infections and gastrointestinal infections with acute or chronic diarrhea. 
     
     
         27 . The strain according to  claim 25 , characterized in that said malabsorption syndromes comprise disorders affecting the anatomy of the intestine such as the short bowel syndrome, and disorders affecting the physiology of the intestine such as cystic fibrosis of the pancreas, malabsoprtion of sugars especially lactose, alterations of lipid absorption, food allergies, and inflammatory bowel diseases such as Crohn's disease and ulcerative colitis.